telacebec: Clinical Trials

3 completed, 1 recruiting, 1 terminated. 3 Phase 2, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Completed 1, Recruiting 1, Terminated 1
Phase 1	2	Completed 2

Follow telacebec: new trials by email Literature Review of telacebec trials Research Report on telacebec

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU) Telacebec - Buruli Ulcer	Phase 2	Recruiting	Barwon Health	200	2024-07-09	2026-06-30
A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients Telacebec, COVID-19 Standard of care - COVID-19 Virus Infection	Phase 2	Terminated	Qurient Co., Ltd.	1	2021-07-29	2022-03-02
A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) Telacebec (Q203), Rifafour e-275 - Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB	Phase 2	Completed	Qurient Co., Ltd.	60	2018-07-23	2019-09-10
A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers Q203, Placebo - Healthy Volunteers	Phase 1	Completed	Qurient Co., Ltd.	47	2016-08-01	2018-05-14
A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers Q203, Placebo - Healthy Volunteers	Phase 1	Completed	Qurient Co., Ltd.	56	2015-08-01	2016-12-06

Conditions studied

Buruli Ulcer (1)  ·  COVID-19 (1)  ·  Ulcer (1)

Sponsors

Qurient Co., Ltd. (4)  ·  Barwon Health (1)

Countries

South Africa (2)  ·  United States (2)  ·  Australia (1)

Top investigators

Daniel O'Brien, MD (1)

Results publications

PMID 40116781